Table 2 Iron blood tests and hemoglobin at different time points in the two study groups.

From: Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

 

Transferrin saturation (%)

Ferritin (ng/ml)

Hemoglobin (mg/dl)

Erythropoietin therapy n (%)

Group 1 (FCM therapy)

Baseline (n = 239)

19.4 ± 9

103 ± 83

9.7 ± 1.5

132 (55%)

12-months follow-up (n = 212)

29.9 ± 12

275 ± 151

11.9 ± 1.8

110 (52%)

 

p < 0.05

p < 0.05

p < 0.05

p = 0.8

Baseline (n = 239)

19.4 ± 9

103 ± 83

9.7 ± 1.5

132 (55%)

18-months follow-up (n = 193)

31.0 ± 17

310 ± 193

11.9 ± 1.9

89 (46%)

 

p < 0.05

p < 0.01

p < 0.05

p = 0.3

Group 2 (ferrous sulfate therapy)

Baseline (n = 110)

19.8 ± 8

102 ± 112

9.8 ± 1.6

62 (56%)

12-months follow-up (n = 96)

22.0 ± 11

180 ± 132

10.1 ± 1.8

60 (62%)

 

p = 0.1

p = 0.1

p = 0.4

p = 0.6

Baseline (n = 110)

19.8 ± 8

102 ± 112

9.8 ± 1.6

62 (56%)

18-months follow-up (n = 87)

24.0 ± 12

175 ± 145

9.9 ± 1.7

56 (64%)

 

p = 0.4

p = 0.1

p = 0.7

p = 0.4